Trial Profile
EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Hydroxychloroquine
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PALABA
- 14 Jul 2023 Planned End Date changed from 30 Jun 2024 to 30 Sep 2024.
- 14 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2022 As of 15 Jan 2022, 51 patients have been randomized and 49 have received at least one drug dose.